Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled

Benitec Biopharma Inc.

2023-Q2 EPS reported -$0.55 revenue$14,000

Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.
Cash and cash equivalents $10.5M at Dec 31, 2022, up from $4.1M at June 30, 2022.
First patient enrolled in OPMD natural history study in Jan 2023; part of BB-301 program.
Expects IND/CTA clearance in Q2 2023; first BB-301 dosing anticipated in Q3 2023.
R&D expenses $3.8M, up $0.7M YoY due to toxicology and manufacturing projects.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Benitec Biopharma Inc. reported financial results for Second Fiscal Quarter ended December 31, 2022.

Period: Second Fiscal Quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 13, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2022.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-034348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.